Lartruvo

Country: European Union

Language: Bulgarian

Source: EMA (European Medicines Agency)

Buy It Now

Patient Information leaflet Patient Information leaflet (PIL)
02-09-2019
Summary of Product characteristics Summary of Product characteristics (SPC)
02-09-2019
Public Assessment Report Public Assessment Report (PAR)
02-09-2019

Active ingredient:

Olaratumab

Available from:

Eli Lilly Nederland B.V.

ATC code:

L01XC27

INN (International Name):

olaratumab

Therapeutic group:

Антинеопластични средства

Therapeutic area:

саркома

Therapeutic indications:

Lartruvo е показан в комбинация с доксорубицин за лечение на възрастни пациенти с напреднал приемателя, които не подлежат на лечение с операция или лъчетерапия и които не са били предварително третирани с доксорубицин (вж. раздел 5.

Product summary:

Revision: 3

Authorization status:

Отменено

Authorization date:

2016-11-09

Patient Information leaflet

                                1
ПРИЛОЖЕНИЕ I
КРАТКА ХАРАКТЕРИСТИКА НА ПРОДУКТА
Лекарствен продукт с невалидно
разрешение за употреба
2
Този лекарствен продукт подлежи на
допълнително наблюдение. Това ще
позволи бързото
установяване на нова информация
относно безопасността. От
медицинските специалисти се
изисква да съобщават всяка подозирана
нежелана реакция. За начина на
съобщаване на
нежелани реакции вижте точка 4.8.
1.
ИМЕ НА ЛЕКАРСТВЕНИЯ ПРОДУКТ
Lartruvo 10 mg/ml концентрат за инфузионен
разтвор
2.
КАЧЕСТВЕН И КОЛИЧЕСТВЕН СЪСТАВ
Един ml от концентрата за инфузионен
разтвор съдържа 10 mg оларатумаб (olaratumab).
Всеки флакон от 19 ml съдържа 190 mg
оларатумаб.
Всеки флакон от 50 ml съдържа 500 mg
оларатумаб.
Оларатумаб е човешко IgG1 моноклонално
антитяло, получено в миши (NS0) клетки
чрез
рекомбинантна ДНК технология.
Помощно вещество с известно действие
Всеки флакон от 19 ml съдържа
приблизително 22 mg (1 mmol) натрий.
Всеки флакон от 50 ml съдържа
приблизително 57 mg (2,5 mmol) натрий.
За пълния списък на помощните
вещества вижте точка 6.1.
3.
ЛЕКАРСТВЕНА ФОРМА
Концентрат за инфузионен разтвор
(стерилен концентрат)
Концентратът е бистър до слабо
опалесцентен и безцветен до бле
                                
                                Read the complete document

Summary of Product characteristics

                                1
ПРИЛОЖЕНИЕ I
КРАТКА ХАРАКТЕРИСТИКА НА ПРОДУКТА
Лекарствен продукт с невалидно
разрешение за употреба
2
Този лекарствен продукт подлежи на
допълнително наблюдение. Това ще
позволи бързото
установяване на нова информация
относно безопасността. От
медицинските специалисти се
изисква да съобщават всяка подозирана
нежелана реакция. За начина на
съобщаване на
нежелани реакции вижте точка 4.8.
1.
ИМЕ НА ЛЕКАРСТВЕНИЯ ПРОДУКТ
Lartruvo 10 mg/ml концентрат за инфузионен
разтвор
2.
КАЧЕСТВЕН И КОЛИЧЕСТВЕН СЪСТАВ
Един ml от концентрата за инфузионен
разтвор съдържа 10 mg оларатумаб (olaratumab).
Всеки флакон от 19 ml съдържа 190 mg
оларатумаб.
Всеки флакон от 50 ml съдържа 500 mg
оларатумаб.
Оларатумаб е човешко IgG1 моноклонално
антитяло, получено в миши (NS0) клетки
чрез
рекомбинантна ДНК технология.
Помощно вещество с известно действие
Всеки флакон от 19 ml съдържа
приблизително 22 mg (1 mmol) натрий.
Всеки флакон от 50 ml съдържа
приблизително 57 mg (2,5 mmol) натрий.
За пълния списък на помощните
вещества вижте точка 6.1.
3.
ЛЕКАРСТВЕНА ФОРМА
Концентрат за инфузионен разтвор
(стерилен концентрат)
Концентратът е бистър до слабо
опалесцентен и безцветен до бле
                                
                                Read the complete document

Similar products

Active ingredient Olaratumab

Olaratumab

ATC code L01XC27

L01XC27

Marketed by Eli Lilly Nederland B.V.

Eli Lilly Nederland B.V.

INN (International Name) olaratumab

olaratumab

Documents in other languages

Patient Information leaflet Patient Information leaflet Spanish 02-09-2019
Summary of Product characteristics Summary of Product characteristics Spanish 02-09-2019
Public Assessment Report Public Assessment Report Spanish 02-09-2019
Patient Information leaflet Patient Information leaflet Czech 02-09-2019
Summary of Product characteristics Summary of Product characteristics Czech 02-09-2019
Public Assessment Report Public Assessment Report Czech 02-09-2019
Patient Information leaflet Patient Information leaflet Danish 02-09-2019
Summary of Product characteristics Summary of Product characteristics Danish 02-09-2019
Public Assessment Report Public Assessment Report Danish 02-09-2019
Patient Information leaflet Patient Information leaflet German 02-09-2019
Summary of Product characteristics Summary of Product characteristics German 02-09-2019
Public Assessment Report Public Assessment Report German 02-09-2019
Patient Information leaflet Patient Information leaflet Estonian 02-09-2019
Summary of Product characteristics Summary of Product characteristics Estonian 02-09-2019
Public Assessment Report Public Assessment Report Estonian 02-09-2019
Patient Information leaflet Patient Information leaflet Greek 02-09-2019
Summary of Product characteristics Summary of Product characteristics Greek 02-09-2019
Public Assessment Report Public Assessment Report Greek 02-09-2019
Patient Information leaflet Patient Information leaflet English 02-09-2019
Summary of Product characteristics Summary of Product characteristics English 02-09-2019
Public Assessment Report Public Assessment Report English 02-09-2019
Patient Information leaflet Patient Information leaflet French 02-09-2019
Summary of Product characteristics Summary of Product characteristics French 02-09-2019
Public Assessment Report Public Assessment Report French 02-09-2019
Patient Information leaflet Patient Information leaflet Italian 02-09-2019
Summary of Product characteristics Summary of Product characteristics Italian 02-09-2019
Public Assessment Report Public Assessment Report Italian 02-09-2019
Patient Information leaflet Patient Information leaflet Latvian 02-09-2019
Summary of Product characteristics Summary of Product characteristics Latvian 02-09-2019
Public Assessment Report Public Assessment Report Latvian 02-09-2019
Patient Information leaflet Patient Information leaflet Lithuanian 02-09-2019
Summary of Product characteristics Summary of Product characteristics Lithuanian 02-09-2019
Public Assessment Report Public Assessment Report Lithuanian 02-09-2019
Patient Information leaflet Patient Information leaflet Hungarian 02-09-2019
Summary of Product characteristics Summary of Product characteristics Hungarian 02-09-2019
Public Assessment Report Public Assessment Report Hungarian 02-09-2019
Patient Information leaflet Patient Information leaflet Maltese 02-09-2019
Summary of Product characteristics Summary of Product characteristics Maltese 02-09-2019
Public Assessment Report Public Assessment Report Maltese 02-09-2019
Patient Information leaflet Patient Information leaflet Dutch 02-09-2019
Summary of Product characteristics Summary of Product characteristics Dutch 02-09-2019
Public Assessment Report Public Assessment Report Dutch 02-09-2019
Patient Information leaflet Patient Information leaflet Polish 02-09-2019
Summary of Product characteristics Summary of Product characteristics Polish 02-09-2019
Public Assessment Report Public Assessment Report Polish 02-09-2019
Patient Information leaflet Patient Information leaflet Portuguese 02-09-2019
Summary of Product characteristics Summary of Product characteristics Portuguese 02-09-2019
Public Assessment Report Public Assessment Report Portuguese 02-09-2019
Patient Information leaflet Patient Information leaflet Romanian 02-09-2019
Summary of Product characteristics Summary of Product characteristics Romanian 02-09-2019
Public Assessment Report Public Assessment Report Romanian 02-09-2019
Patient Information leaflet Patient Information leaflet Slovak 02-09-2019
Summary of Product characteristics Summary of Product characteristics Slovak 02-09-2019
Public Assessment Report Public Assessment Report Slovak 23-11-2016
Patient Information leaflet Patient Information leaflet Slovenian 02-09-2019
Summary of Product characteristics Summary of Product characteristics Slovenian 02-09-2019
Public Assessment Report Public Assessment Report Slovenian 02-09-2019
Patient Information leaflet Patient Information leaflet Finnish 02-09-2019
Summary of Product characteristics Summary of Product characteristics Finnish 02-09-2019
Public Assessment Report Public Assessment Report Finnish 02-09-2019
Patient Information leaflet Patient Information leaflet Swedish 02-09-2019
Summary of Product characteristics Summary of Product characteristics Swedish 02-09-2019
Public Assessment Report Public Assessment Report Swedish 02-09-2019
Patient Information leaflet Patient Information leaflet Norwegian 02-09-2019
Summary of Product characteristics Summary of Product characteristics Norwegian 02-09-2019
Patient Information leaflet Patient Information leaflet Icelandic 02-09-2019
Summary of Product characteristics Summary of Product characteristics Icelandic 02-09-2019
Patient Information leaflet Patient Information leaflet Croatian 02-09-2019
Summary of Product characteristics Summary of Product characteristics Croatian 02-09-2019
Public Assessment Report Public Assessment Report Croatian 02-09-2019

Search alerts related to this product

Alerts Lartruvo Olaratumab

Lartruvo Olaratumab

View documents history

Documents history Documents history

Lartruvo